MRC Agrotech Ltd Reports Strong FY26 Growth Amid Strategic Acquisition

MRC Agrotech Ltd's consolidated profit for FY26 stood at ₹1.32 crore, marking a 33% increase from ₹0.99 crore in FY25. Consolidated revenue grew significantly to ₹89.88 crore from ₹33.31 crore in the previous year.

Reader Takeaway: Strong FY26 growth driven by acquisition; auditor flags concentration risks.

What just happened

MRC Agrotech Ltd has reported its financial results for the fiscal year ending March 31, 2026. The company's consolidated revenue surged to ₹89.88 crore (₹8,988.08 lakh), compared to ₹33.31 crore in FY25. Consolidated profit after tax also saw a substantial jump, reaching ₹1.32 crore (₹131.69 lakh) from ₹0.99 crore in FY25.

Why this matters

The substantial growth in revenue and profit for FY26 indicates improved business performance. The acquisition of Marsapi Lifesciences Private Limited, a 100% takeover through a share-swap arrangement, is a key strategic move that likely contributed to the top-line expansion. This acquisition was executed by issuing 86,42,097 equity shares at ₹19.50 per share, with no cash consideration involved.

The backstory

In the previous fiscal year, FY25, MRC Agrotech had reported consolidated revenue of ₹33.31 crore and a profit of ₹0.99 crore. The significant jump in FY26 figures shows a considerable acceleration in the company's financial trajectory. The company also undertook steps to manage its liquidity by assigning receivables totaling ₹7.30 crore to Cicago Commodities Private Limited on a non-recourse basis to settle trade creditor dues.

What changes now

The acquisition of Marsapi Lifesciences integrates a new entity into MRC Agrotech's operations, potentially expanding its market reach or product portfolio. The company's focus on managing its financial obligations through receivable assignments also suggests a proactive approach to working capital management. The share-swap mechanism for the acquisition indicates a strategic decision to use equity rather than cash, preserving liquidity.

Risks to watch

Auditors have raised concerns regarding trading concentration, noting that two counterparties accounted for approximately 53% of purchases and 23% of sales. A significant portion of business, 44.62% of total taxable outward supplies, was recognized in March 2026, pointing to year-end concentration. Additionally, an inconsistency was found in GSTR-3B filings where exempt agricultural sales were not bifurcated from taxable supplies, although the company clarified these as exempt and auditors advised correction. Despite these points, the auditor issued an unmodified opinion.

Peer comparison

While specific peer data for FY26 is not provided in the filing, MRC Agrotech's revenue growth from ₹33.31 crore to ₹89.88 crore represents a more than 160% increase. Its profit also grew by over 33%. This performance needs to be evaluated against the sector's average growth rates and profitability metrics for the agrochemical and life sciences sectors.

Context metrics (time-bound)

• FY26 Standalone Revenue: ₹85.46 crore (up from ₹32.45 crore in FY25)
• FY26 Standalone Profit: ₹1.17 crore (up from ₹0.88 crore in FY25)
• FY26 Consolidated Revenue: ₹89.88 crore (up from ₹33.31 crore in FY25)
• FY26 Consolidated Profit: ₹1.32 crore (up from ₹0.99 crore in FY25)
• Acquisition: 100% of Marsapi Lifesciences via share swap (86,42,097 equity shares at ₹19.50 each)
• Receivables Assignment: ₹7.30 crore to Cicago Commodities Private Limited

What to track next

Investors will be keen to see how MRC Agrotech integrates Marsapi Lifesciences and diversifies its counterparty base to mitigate the identified trading concentration risk. Monitoring the precision in GST reporting and overall business activity spread across the fiscal year will also be crucial for assessing sustainable growth and compliance.